Skip to main content
SpringerLink
Log in

Mehrfach zielgerichtete Therapie beim Mammakarzinom

Was künftig zu kombinieren ist

Multiple targeted therapy for breast cancer

What will be combined in the future

  • Gynäkologie aktuell
  • Published:
Der Gynäkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. http://www.AGOonline.org

  2. Baselga J, Campone M, Piccart M et al (2011) Everolismus in postmenopausal hormone-receptor-positive advanced breast cancer. N Eng J Med

  3. Bachelot T, Bourgier C, Cropet C et al (2012) Randomized phase 2 trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive human epidermal growth factor 2 receptor-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:2718–2724

    Article  PubMed  CAS  Google Scholar 

  4. Finn S et al (2012) Results of a randomized phase 2 study of PD0332991, a cyclin dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for the first-line treatment of ER+/HER2- advanced breast cancer. Cancer Res 72(24suppl) (abst S 1–6)

  5. Huober J, Fasching PA, Barsoum M et al (2012) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – results of the eLEcTRA trial. Breast 21:27−33

    Article  PubMed  CAS  Google Scholar 

  6. Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor–positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529–5537

    Article  PubMed  CAS  Google Scholar 

  7. Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

    Article  PubMed  CAS  Google Scholar 

  8. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  9. Arteaga C, Sliwkowski MX, Osborne K et al (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32

    Article  CAS  Google Scholar 

  10. Geyer CE, Foster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2 positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  11. Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130

    Article  PubMed  CAS  Google Scholar 

  12. Lin NU et al (2011) TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). J Clin Oncol 29 (suppl; abstr 528)

  13. Chang JCN (2011) TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol 29 (suppl; abstr 505)2.24

  14. Baselga J, Bradbury I, Eidtmann H et al (2012) First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized open label multicenter phase 3 trial. Lancet 379:633−640

    Article  PubMed  CAS  Google Scholar 

  15. Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144

    Article  PubMed  CAS  Google Scholar 

  16. Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119

    Article  PubMed  CAS  Google Scholar 

  17. Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 1:25–32

    Article  Google Scholar 

  18. Schneeweiss A, Chia S, Hickish T et al (2011) Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res 71(suppl 24):112s

    Article  Google Scholar 

  19. Andre F, Campone M, O’Regan R et al (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28:5110–5115

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehung/en hin: SH Beratungstätigkeit (Advisory Board) Roche, GSK, Novartis. Research funding: GSK. WJ Research grants and honoraria from: Roche, GSK, Novartis.

Author information

Authors and Affiliations

  1. Frauenklinik,Konservative Gynäkologische Onkologie, Klinikum der Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland

    J. Huober

  2. Universitätsfrauenklinik Ulm, Ulm, Deutschland

    J. Salmen & W. Janni

Authors
  1. J. Huober
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Salmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Janni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Huober.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huober, J., Salmen, J. & Janni, W. Mehrfach zielgerichtete Therapie beim Mammakarzinom. Gynäkologe 46, 267–272 (2013). https://doi.org/10.1007/s00129-013-3141-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-013-3141-y

Search

Navigation